Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Group CBT for Depression and AOD Disorders (BRIGHT2)

This study has been completed.
Sponsor:
Collaborator:
Behavioral Health Services, Inc.
Information provided by (Responsible Party):
RAND
ClinicalTrials.gov Identifier:
NCT01154309
First received: June 29, 2010
Last updated: November 10, 2011
Last verified: November 2011

June 29, 2010
November 10, 2011
September 2006
September 2009   (final data collection date for primary outcome measure)
  • Reductions in depressive symptoms as measured by the BDI II [ Time Frame: Post treatment ] [ Designated as safety issue: No ]
  • Reductions in AOD use [ Time Frame: Post treatment ] [ Designated as safety issue: No ]
  • Reductions in depressive symptoms as measured by the BDI II [ Time Frame: At immediate post-intervention and 3 month follow-up ] [ Designated as safety issue: No ]
  • Reductions in AOD use [ Time Frame: Immediate post-intervention and 3 months later ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01154309 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Group CBT for Depression and AOD Disorders
Group Cognitive Behavioral Therapy for Depression and Alcohol and Other Drug Disorders

The investigators will adapt and test an existing treatment (group CBT for depression) for use in outpatient substance use treatment settings as delivered by trained substance use counselors. The investigators expect that treatment will lead to improved depression and substance use outcomes.

Aim 1. To adapt an existing group therapy (CBT for depression), creating a manualized treatment and accompanying implementation measures and tools for use with clients with persistent depressive symptoms and AOD disorders and to obtain preliminary assessments of the treatment from patient and provider perspectives.

Aim 2. To conduct a pilot test of the revised treatment in which we (a) demonstrate that when the therapy is implemented with fidelity, clinically significant reductions in depressive symptoms and AOD use occur; (b) estimate the likely effect size; and (c) investigate the underlying mechanisms of change, including both cognitive-behavioral and group processes and their relationship to depression and AOD treatment outcomes.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Depression
  • Substance Use
Behavioral: Group CBT for Depression and AOD Disorders
18 sessions of 2-hour group CBT
  • Experimental: 1
    Clients are invited to attend 18 group CBT sessions
    Intervention: Behavioral: Group CBT for Depression and AOD Disorders
  • No Intervention: 2
    Clients receive usual care
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
73
September 2009
September 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Enrolled in outpatient substance abuse program
  • BDI II score >13
  • Probable alcohol or substance use problem

Exclusion Criteria:

  • Cognitive impairment (Short Blessed > 10)
  • Probably bipolar or schizophrenic disorder
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01154309
R01DA020159
Yes
RAND
RAND
Behavioral Health Services, Inc.
Principal Investigator: Katherine E Watkins, MD, MSHS RAND
RAND
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP